EU/3/03/157: Orphan designation for the treatment of cystic fibrosis

Recombinant dog gastric lipase

Table of contents


On 9 July 2003, orphan designation (EU/3/03/157) was granted by the European Commission to Meristem Therapeutics S.A., France, for recombinant dog gastric lipase for the treatment of cystic fibrosis.

Key facts

Active substance
Recombinant dog gastric lipase
Intended use
Treatment of cystic fibrosis
Orphan designation status
EU designation number
Date of designation
Meristem Therapeutics S.A.
8 rue de Frères Lumière
F-61300 Clermont Ferrand
Telephone: (33-4) 73 98 68 10
Telefax: (33-4) 73 98 68 19

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating